O	0	6	Pegase
O	7	9	03
O	9	10	:
O	11	12	a
O	13	24	prospective
O	25	35	randomized
O	36	41	phase
O	42	45	III
O	46	51	trial
O	52	54	of
O	55	58	FEC
O	59	63	with
O	64	66	or
O	67	74	without
B-intervention	75	79	high
I-intervention	79	80	-
I-intervention	80	84	dose
I-intervention	85	93	thiotepa
I-intervention	93	94	,
I-intervention	95	111	cyclophosphamide
O	112	115	and
O	116	126	autologous
O	127	131	stem
O	132	136	cell
O	137	152	transplantation
O	153	155	in
O	156	161	first
O	161	162	-
O	162	166	line
O	167	176	treatment
O	177	179	of
O	180	190	metastatic
O	191	197	breast
O	198	204	cancer
O	204	205	.

O	206	212	Pegase
O	213	215	03
O	216	218	is
O	219	220	a
O	221	232	multicenter
O	233	244	prospective
O	245	255	randomized
O	256	261	phase
O	262	265	III
O	266	271	trial
O	272	282	evaluating
O	283	286	the
O	287	293	impact
O	294	296	of
O	297	302	first
O	302	303	-
O	303	307	line
O	308	312	high
O	312	313	-
O	313	317	dose
O	318	330	chemotherapy
O	331	332	(
O	332	335	HDC
O	335	336	)
O	337	341	with
O	342	346	stem
O	347	351	cell
O	352	359	support
O	360	362	on
O	363	370	overall
O	371	379	survival
O	380	381	(
O	381	383	OS
O	383	384	)
O	384	385	,
O	386	393	disease
O	393	394	-
O	394	398	free
O	399	407	survival
O	408	409	(
O	409	412	DFS
O	412	413	)
O	414	417	and
O	418	426	response
O	427	431	rate
O	432	434	in
B-total-participants	435	438	308
B-eligibility	439	447	patients
I-eligibility	448	452	with
I-eligibility	453	467	histologically
I-eligibility	468	474	proven
I-eligibility	475	485	metastatic
I-eligibility	486	492	breast
I-eligibility	493	499	cancer
I-eligibility	500	510	responding
I-eligibility	511	513	to
I-eligibility	514	523	induction
I-eligibility	524	531	therapy
O	531	532	.

O	533	541	Eligible
O	542	550	patients
O	551	559	received
O	560	564	four
O	565	574	induction
O	575	581	cycles
O	582	586	with
O	587	590	FEC
O	591	594	100
O	595	596	(
O	596	597	5
O	597	598	-
O	598	610	fluorouracil
O	611	614	500
O	615	617	mg
O	617	618	/
O	618	619	m
O	619	620	(
O	620	621	2
O	621	622	)
O	622	623	,
O	624	634	epirubicin
O	635	638	100
O	639	641	mg
O	641	642	/
O	642	643	m
O	643	644	(
O	644	645	2
O	645	646	)
O	646	647	,
O	648	664	cyclophosphamide
O	665	668	500
O	669	671	mg
O	671	672	/
O	672	673	m
O	673	674	(
O	674	675	2
O	675	676	)
O	676	677	)
O	677	678	.

O	679	687	Patients
O	688	692	with
O	693	702	objective
O	703	711	response
O	712	713	(
O	713	714	N
O	714	715	=
B-total-participants	715	718	179
O	718	719	)
O	720	724	were
O	725	735	randomized
O	736	738	to
O	739	742	one
O	743	748	cycle
O	749	751	of
O	752	755	HDC
O	756	757	(
O	757	773	cyclophosphamide
O	774	778	6000
O	779	781	mg
O	781	782	/
O	782	783	m
O	783	784	(
O	784	785	2
O	785	786	)
O	787	790	and
O	791	799	thiotepa
O	800	803	800
O	804	806	mg
O	806	807	/
O	807	808	m
O	808	809	(
O	809	810	2
O	810	811	)
O	812	813	(
O	813	817	CHUT
O	817	818	)
O	818	819	)
O	820	823	and
O	824	828	stem
O	829	833	cell
O	834	841	support
O	842	843	(
O	843	844	N
O	844	845	=
B-intervention-participants	845	847	88
O	847	848	)
O	848	849	,
O	850	852	or
B-control	853	855	no
I-control	856	863	further
I-control	864	873	treatment
O	874	875	(
O	875	876	N
O	876	877	=
B-control-participants	877	879	91
O	879	880	)
O	880	881	.

O	882	885	All
O	886	894	patients
O	895	899	were
O	900	908	observed
O	909	914	until
O	915	922	disease
O	923	934	progression
O	935	937	or
O	938	943	death
O	943	944	.

B-iv-bin-abs	945	948	One
B-outcome	949	954	toxic
I-outcome	955	960	death
O	961	969	occurred
O	970	975	after
O	976	980	CHUT
O	980	981	.

O	982	987	Other
O	988	998	toxicities
O	999	1003	were
O	1004	1014	manageable
O	1014	1015	.

O	1016	1019	The
B-outcome	1020	1028	response
I-outcome	1029	1033	rate
I-outcome	1034	1036	at
I-outcome	1037	1038	3
I-outcome	1039	1045	months
O	1046	1049	was
O	1050	1056	higher
O	1057	1059	in
O	1060	1063	the
O	1064	1079	intensification
O	1080	1083	arm
O	1083	1084	:
B-iv-bin-percent	1085	1087	82
I-iv-bin-percent	1087	1088	.
I-iv-bin-percent	1088	1089	7
I-iv-bin-percent	1089	1090	%
O	1091	1092	(
B-iv-bin-percent	1092	1094	25
I-iv-bin-percent	1094	1095	.
I-iv-bin-percent	1095	1096	3
I-iv-bin-percent	1096	1097	%
B-outcome	1098	1106	complete
I-outcome	1107	1115	response
I-outcome	1116	1117	(
I-outcome	1117	1119	CR
I-outcome	1119	1120	)
O	1120	1121	)
O	1122	1128	versus
B-cv-bin-percent	1129	1131	59
I-cv-bin-percent	1131	1132	.
I-cv-bin-percent	1132	1133	2
I-cv-bin-percent	1133	1134	%
O	1135	1136	(
B-cv-bin-percent	1136	1138	14
I-cv-bin-percent	1138	1139	.
I-cv-bin-percent	1139	1140	1
I-cv-bin-percent	1140	1141	%
O	1142	1144	CR
O	1144	1145	)
O	1146	1147	(
O	1147	1148	P
O	1148	1149	=
O	1149	1150	0
O	1150	1151	.
O	1151	1155	0002
O	1155	1156	)
O	1156	1157	.

O	1158	1164	Median
O	1165	1171	follow
O	1171	1172	-
O	1172	1174	up
O	1175	1178	was
O	1179	1181	48
O	1182	1188	months
O	1188	1189	.

B-outcome	1190	1196	Median
I-outcome	1197	1200	DFS
O	1201	1204	was
B-iv-cont-median	1205	1207	11
O	1208	1211	and
B-cv-cont-median	1212	1213	6
I-cv-cont-median	1213	1214	.
I-cv-cont-median	1214	1215	6
I-cv-cont-median	1216	1222	months
O	1223	1225	in
O	1226	1229	the
O	1230	1245	intensification
O	1246	1249	and
O	1250	1253	the
O	1254	1265	observation
O	1266	1270	arms
O	1270	1271	,
O	1272	1284	respectively
O	1285	1286	(
O	1286	1287	P
O	1287	1288	=
O	1288	1289	0
O	1289	1290	.
O	1290	1294	0001
O	1294	1295	)
O	1295	1296	.

O	1297	1302	There
O	1303	1306	was
O	1307	1309	no
B-outcome	1310	1318	survival
O	1319	1329	difference
O	1329	1330	:
B-iv-bin-percent	1331	1333	33
I-iv-bin-percent	1333	1334	.
I-iv-bin-percent	1334	1335	6
O	1336	1342	versus
B-cv-bin-percent	1343	1345	27
I-cv-bin-percent	1345	1346	.
I-cv-bin-percent	1346	1347	3
I-cv-bin-percent	1347	1348	%
B-outcome	1349	1351	OS
I-outcome	1352	1354	at
I-outcome	1355	1356	3
I-outcome	1357	1362	years
O	1363	1364	(
O	1364	1365	P
O	1365	1366	=
O	1366	1367	0
O	1367	1368	.
O	1368	1369	8
O	1369	1370	)
O	1371	1374	and
B-iv-cont-median	1375	1377	22
I-iv-cont-median	1377	1378	.
I-iv-cont-median	1378	1379	9
O	1380	1386	versus
B-cv-cont-median	1387	1389	22
I-cv-cont-median	1389	1390	.
I-cv-cont-median	1390	1391	3
I-cv-cont-median	1392	1398	months
B-outcome	1399	1405	median
I-outcome	1406	1410	time
I-outcome	1411	1413	to
I-outcome	1414	1421	relapse
O	1422	1424	in
O	1425	1428	the
O	1429	1444	intensification
O	1445	1448	and
O	1449	1460	observation
O	1461	1465	arms
O	1465	1466	,
O	1467	1479	respectively
O	1479	1480	.

O	1481	1483	In
O	1484	1488	this
O	1489	1499	randomized
O	1500	1505	trial
O	1505	1506	,
O	1507	1510	HDC
O	1511	1515	with
O	1516	1520	CHUT
O	1521	1529	improved
O	1530	1533	DFS
O	1534	1537	but
O	1538	1541	not
O	1542	1544	OS
O	1544	1545	,
O	1546	1559	corroborating
O	1560	1568	findings
O	1569	1573	from
O	1574	1581	earlier
O	1582	1588	trials
O	1588	1589	.
